Michael Kauffman appointed as Chairman of the Board of FoRx Therapeutics AG

Basel, Switzerland, 15 May 2024 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the appointment of Michael Kauffman as Chairman of the Board.

Dr Kauffman has over 25 years of experience in the life sciences industry, including expertise in preclinical research, clinical development, regulatory strategy and oncology commercialization. He currently serves as Chief Executive Officer (CEO), President and Board Member of Nereid Therapeutics Inc. In addition to FoRx and Nereid, he is a Board Member for Verastem Oncology, Kezar Life Sciences, Incendia Therapeutics and BiVictriX Therapeutics.

Previously, Dr Kauffman served as the co-founder and CEO of Karyopharm, where he guided the Company’s transition from a start-up biotechnology company to a commercial stage organization and the global approvals of XPOVIO®. Prior to joining Karyopharm, Dr Kauffman was CMO of Onyx Pharma, where he led the development of Kyprolis® following the Onyx acquisition of Proteolix Inc., where he served as Board Member and then CMO. Previously, Dr. Kauffman was President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals and has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman received his MD and PhD from Johns Hopkins Medical School, trained in Internal Medicine at Beth Israel (Deaconess) Medical Center and in Rheumatology at Massachusetts General Hospital, and is board certified in Internal Medicine.

About FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways activated in cancer. Drawing on discoveries by Prof. Thanos Halazonetis and Dr. Sotirios Sotiriou, FoRx was co-founded in 2019 with M Ventures, Novartis Venture Fund and Omega Funds along with Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), and LSP (Life Science Partners, now EQT Life Sciences). For more information, visit www.forxtherapeutics.com